Key Highlights
- Margaret Koziel, M.D., appointed as Chief Medical Officer at Boston Pharmaceuticals.
- Juan Carlos Lopez-Talavera, M.D., Ph.D., transitions to advisory role.
- Dr. Koziel brings 16 years of drug development and executive leadership experience.
- Focus on advancing BOS-580, a promising treatment for MASH.
- Dr. Koziel’s background includes roles at Innoviva, Axcella, Kaleido Biosciences, Vertex, and Novartis.
Source: Business Wire
Notable Quotes
- “Boston Pharmaceuticals is at an exciting time as we advance our lead program BOS-580 with biopsy results expected soon in patients with stage F2 and F3 disease. We are committed to building a strong organizational structure and leadership team. Dr. Koziel’s rich experience and deep scientific expertise in liver disease are instrumental in achieving our next developmental milestones.” — Sophie Kornowski, CEO at Boston Pharmaceuticals
- “I am excited to join Boston Pharmaceuticals at this pivotal juncture. Backed by a skilled team and strong partnerships, the company is poised to move BOS-580 swiftly and successfully through clinical development to meet patient needs.” — Margaret Koziel, M.D., Chief Medical Officer at Boston Pharmaceuticals
SoHC's Take
The appointment of Dr. Margaret Koziel as Chief Medical Officer at Boston Pharmaceuticals marks a significant strategic move for the company. With Dr. Koziel’s extensive background in drug development and executive leadership, particularly in the areas of liver disease and metabolic disorders, Boston Pharmaceuticals is well-positioned to advance its lead candidate BOS-580. This investigational FGF21 analogue for MASH treatment represents a promising therapeutic option for patients with severe liver conditions. Dr. Koziel’s expertise will be invaluable as the company navigates the critical phases of clinical development and works towards delivering impactful treatments to address unmet medical needs in hepatology.
